Pharma Mar S.A. | Large-cap | Healthcare
€79.10
0.32%
| Pharma Mar S.A Stock Comparison:
Pharma Mar S.A vs Atrys Health S.APharma Mar S.A vs Oryzon Genomics S.APharma Mar S.A vs Vytrus Biotech S.APharma Mar S.A vs Biotechnology AssetsPharma Mar S.A vs Grifols, S.APharma Mar S.A vs IBEX 35 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 56.4M
Gross Profit 53.6M 95.07%
Operating Income 24.1M 42.75%
Net Income 23.4M 41.44%

Balance Sheet Metrics

Total Assets 333.5M
Total Liabilities 136.0M
Shareholders Equity 197.5M
Debt to Equity 0.69

Cash Flow Metrics

Operating Cash Flow -1.6M
Free Cash Flow -6.8M

Revenue & Profitability Trend

Pharma Mar S.A Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i174.9M158.2M196.3M229.8M270.0M
Cost of Goods Sold i8.2M9.6M13.6M16.4M13.7M
Gross Profit i166.7M148.5M182.7M213.4M256.2M
Gross Margin % i95.3%93.9%93.1%92.8%94.9%
Operating Expenses
Research & Development i103.5M99.3M83.4M72.2M53.8M
Selling, General & Administrative i-2.7M41.8M43.2M39.7M35.8M
Other Operating Expenses i25.4M12.8M15.2M10.9M11.6M
Total Operating Expenses i126.2M153.9M141.9M122.8M101.1M
Operating Income i6.3M-4.1M44.4M92.4M156.2M
Operating Margin % i3.6%-2.6%22.6%40.2%57.9%
Non-Operating Items
Interest Income i5.7M4.1M875.0K370.0K336.0K
Interest Expense i2.5M2.4M2.4M3.4M3.1M
Other Non-Operating Income-----
Pre-tax Income i12.0M-3.6M43.8M95.1M145.6M
Income Tax i-14.1M-4.8M-5.6M2.3M8.3M
Effective Tax Rate % i-118.0%0.0%-12.7%2.4%5.7%
Net Income i26.1M1.1M49.4M92.9M137.3M
Net Margin % i14.9%0.7%25.1%40.4%50.8%
Key Metrics
EBITDA i21.0M4.1M54.3M104.0M156.2M
EPS (Basic) i€1.49€0.06€2.73€5.14€7.50
EPS (Diluted) i€1.49€0.06€2.73€5.13€7.50
Basic Shares Outstanding i1753900017900000180500001807000018293000
Diluted Shares Outstanding i1753900017900000180500001807000018293000

Income Statement Trend

Pharma Mar S.A Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i63.2M60.0M149.8M113.3M96.2M
Short-term Investments i91.3M102.5M32.6M88.5M99.3M
Accounts Receivable i34.3M27.2M29.0M50.6M23.7M
Inventory i50.9M39.3M27.7M10.5M11.9M
Other Current Assets3.6M14.1M23.1M22.6M10.5M
Total Current Assets i250.2M252.6M275.2M295.2M245.7M
Non-Current Assets
Property, Plant & Equipment i3.6M22.4M23.6M23.9M23.6M
Goodwill i1.0M1.9M2.6M3.2M3.9M
Intangible Assets i1.0M1.9M2.6M3.2M3.9M
Long-term Investments-----
Other Non-Current Assets-----
Total Non-Current Assets i99.4M87.9M118.1M73.2M84.6M
Total Assets i349.6M340.5M393.3M368.4M330.3M
Liabilities
Current Liabilities
Accounts Payable i38.6M29.2M27.5M26.9M21.0M
Short-term Debt i9.8M14.8M14.7M14.0M16.8M
Current Portion of Long-term Debt-----
Other Current Liabilities13.9M15.8M19.4M5.8M4.9M
Total Current Liabilities i82.7M95.9M97.3M86.3M94.9M
Non-Current Liabilities
Long-term Debt i41.2M28.9M27.9M35.3M39.9M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities194.0K193.0K186.0K186.0K176.0K
Total Non-Current Liabilities i58.6M51.2M73.0M104.1M132.6M
Total Liabilities i141.3M147.1M170.3M190.5M227.5M
Equity
Common Stock i10.9M11.0M11.0M11.0M11.0M
Retained Earnings i168.4M142.2M156.5M121.3M41.9M
Treasury Stock i30.8M31.1M15.9M25.7M21.5M
Other Equity-----
Total Shareholders Equity i208.4M193.4M223.0M177.9M102.7M
Key Metrics
Total Debt i51.1M43.7M42.6M49.3M56.7M
Working Capital i167.6M156.7M177.9M208.9M150.7M

Balance Sheet Composition

Pharma Mar S.A Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i12.0M-3.6M43.8M95.1M145.6M
Depreciation & Amortization i-----
Stock-Based Compensation i0297.0K393.0K339.0K274.0K
Working Capital Changes i-43.0M-36.7M-30.0M-68.6M123.3M
Operating Cash Flow i-35.2M-41.1M16.0M29.7M271.6M
Investing Activities
Capital Expenditures i-14.1M-16.0M-8.8M-7.8M-3.0M
Acquisitions i-----
Investment Purchases i-351.5M-314.3M-219.2M0-116.0M
Investment Sales i367.1M287.2M238.9M26.3M0
Investing Cash Flow i1.5M-43.0M10.9M18.5M-119.0M
Financing Activities
Share Repurchases i-18.7M-37.9M-50.2M-40.7M-63.8M
Dividends Paid i-11.4M-11.7M-11.8M-10.9M-8.8M
Debt Issuance i15.4M6.4M1.5M5.8M834.0K
Debt Repayment i-6.5M-7.5M-10.2M-15.3M-32.4M
Financing Cash Flow i-3.2M-32.1M-13.4M-27.4M-73.9M
Free Cash Flow i-9.5M-29.4M29.5M17.9M275.9M
Net Change in Cash i-36.9M-116.3M13.5M20.7M78.6M

Cash Flow Trend

Pharma Mar S.A Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 33.61
Forward P/E 21.95
Price to Book 6.83
Price to Sales 7.46
PEG Ratio 21.95

Profitability Ratios

Profit Margin 22.20%
Operating Margin 42.83%
Return on Equity 21.94%
Return on Assets 5.91%

Financial Health

Current Ratio 2.84
Debt to Equity 25.51
Beta -0.11

Per Share Data

EPS (TTM) €2.41
Book Value per Share €11.86
Revenue per Share €9.97

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
phm1.4B33.616.8321.94%22.20%25.51
Atrys Health S.A 214.1M-6.690.85-11.73%-14.57%100.85
Oryzon Genomics S.A 203.9M-44.561.96-4.20%-58.55%15.22
Vytrus Biotech S.A 41.4M39.295.6816.23%16.76%24.31
Biotechnology Assets 24.1M10.773.56-44.40%-98.39%31.56
Grifols, S.A 7.9B29.501.714.99%4.00%126.87

Financial data is updated regularly. All figures are in the company's reporting currency.